Our guest is Ben Zeskind, a long-time supporter of Unit 669 and one of the American Friends’ dedicated donors. We were lucky to be introduced to him by our Vice Chairman, Peter Feinberg.
Ben is the co-founder and CEO of Immuneering Corporation, a clinical-stage biotechnology company focused on developing new cancer treatments.


For nearly two decades, Ben has been working on a single mission- to help people with cancer live longer, while preserving their quality of life.
Through Immuneering, he and his team are developing a new class of therapies designed to treat cancer in a more durable and sustainable way.


In this episode, we’ll talk with Ben about what it means to build something over many years and the challenges of working in science and innovation.


Ben's LinkedIn:

https://www.linkedin.com/in/bzeskind/


Immuneering Corporation:

https://immuneering.com/

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör Bar Reuven. Innehållet i podden är skapat av Bar Reuven och inte av, eller tillsammans med, Poddtoppen.